Showing 20 of 85 recruiting trials for “adult-t-cell-leukemialymphoma”
RecruitingNCT06784167 ↗
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
64Cu-LLP2A for Imaging Hematologic Malignancies
👨⚕️ Farrokh Dehdashti, M.D., Washington University School of Medicine📍 1 site📅 Started Feb 2025View details ↗
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RecruitingNCT06788639 ↗
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
RecruitingNCT06821880 ↗
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
A Study of Enasidenib in People With T-Cell Lymphoma
👨⚕️ Zachary Epstein-Peterson, MD, Memorial Sloan Kettering Cancer Center📍 8 sites📅 Started Dec 2024View details ↗
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
👨⚕️ Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Nov 2024View details ↗
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
👨⚕️ Kerry A Rogers, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Nov 2024View details ↗
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingNCT06508684 ↗
Current Status of BTKi Treatment for CLL/SLL in China
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Jul 2024View details ↗
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 73 sites📅 Started May 2024View details ↗
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
👨⚕️ Jianyong Li, PhD, MD, The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Apr 2024View details ↗
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
👨⚕️ Lugui Qiu, M.D., Ph.D., Hematology Hospital of the Chinese Academy of Medical Sciences📍 6 sites📅 Started Apr 2024View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →